At Inotek your vision is our focus. We’re dedicated to scientific innovation and medical research to find solutions that can protect and potentially restore the vision of those suffering from diseases of the eye. Our groundbreaking innovation in adenosine science has yielded a new approach to glaucoma. Trabodenoson is being developed to address both the control of pressure in the eye, as well as the retinal damage that ultimately leads to vision loss. We are committed to achieving this with a much-improved side effect profile relative to existing therapies.
- Inotek Pharmaceuticals Phase 3 Development Plan Conference Call Webcast Visit the Webcast Archive
- Inotek Pharmaceuticals Announces Positive End-of-Phase 2 Meeting with FDA and Phase 3 Development Strategy for Trabodenoson, a Novel Treatment for Glaucoma Read Full Press Release
- Inotek Pharmaceuticals Corporation Appoints Dr. Cadmus Collins Rich as Vice President, Medical Affairs and Clinical Development Read Full Press Release
- Inotek Pharmaceuticals Appoints Richard N. Spivey PharmD, Ph.D. to Board of Directors Read Full Press Release